A new pragmatic design for dose escalation in phase 1 clinical trials using an adaptive continual reassessment method
dc.contributor.author | North, B | en_US |
dc.contributor.author | Kocher, HM | en_US |
dc.contributor.author | Sasieni, P | en_US |
dc.date.accessioned | 2020-05-22T14:12:13Z | |
dc.date.available | 2019-06-06 | en_US |
dc.date.issued | 2019-06-26 | en_US |
dc.identifier.issn | 1471-2407 | en_US |
dc.identifier.other | ARTN 632 | en_US |
dc.identifier.uri | https://qmro.qmul.ac.uk/xmlui/handle/123456789/64289 | |
dc.language.iso | en | en_US |
dc.relation.ispartof | BMC CANCER | en_US |
dc.rights | Creative Commons Attribution 4.0 International License | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
dc.subject | Adaptive design | en_US |
dc.subject | Bayesian adaptive | en_US |
dc.subject | Simulation | en_US |
dc.subject | 3+3 design | en_US |
dc.subject | Maximal tolerated dose | en_US |
dc.subject | Dose-finding | en_US |
dc.subject | CRM | en_US |
dc.subject | Model-based design | en_US |
dc.subject | Rule-based design | en_US |
dc.title | A new pragmatic design for dose escalation in phase 1 clinical trials using an adaptive continual reassessment method | en_US |
dc.type | Article | |
dc.rights.holder | © The Author(s). 2019. | |
dc.identifier.doi | 10.1186/s12885-019-5801-3 | en_US |
pubs.author-url | http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000473007000004&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=612ae0d773dcbdba3046f6df545e9f6a | en_US |
pubs.notes | Not known | en_US |
pubs.publication-status | Published | en_US |
pubs.volume | 19 | en_US |
rioxxterms.funder | Default funder | en_US |
rioxxterms.identifier.project | Default project | en_US |